Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an announcement.
Neuren Pharmaceuticals Limited has announced an update on its ongoing share buy-back program. As of May 1, 2025, the company has repurchased a total of 2,910,919 ordinary fully paid shares, including 34,962 shares bought back on the previous day. This buy-back initiative is part of Neuren’s strategy to optimize its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is listed on the Australian Securities Exchange under the code NEU and is involved in the research and commercialization of pharmaceutical products.
YTD Price Performance: -6.57%
Average Trading Volume: 1,250
Technical Sentiment Signal: Hold
Current Market Cap: $904.2M
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.